| Title |
Levetiracetam monotherapy in patients with brain tumor-related epilepsy: seizure control, safety, and quality of life
|
|---|---|
| Published in |
Journal of Neuro-Oncology, November 2010
|
| DOI | 10.1007/s11060-010-0460-x |
| Pubmed ID | |
| Authors |
Marta Maschio, Loredana Dinapoli, Francesca Sperati, Andrea Pace, Alessandra Fabi, Antonello Vidiri, Paola Muti |
| Abstract |
We performed a case series analysis to evaluate the effects of levetiracetam (LEV) monotherapy on seizures, adverse events, cognitive functioning and quality of life (QoL) in patients with brain tumor-related epilepsy (BTRE). We also explored the possible effects of systemic therapies on the efficacy of LEV. Twenty-nine patients were followed (13 female, 16 male; age 24-75 years) with 12 months of follow-up. Patients were evaluated by QoL and neuropsychological tests. At final follow-up, mean LEV dosage was 1991.4 mg/day. Among patients who reached the final follow-up of 12 months (n = 15), 1 patient had ≥50% reduction of seizure frequency (SF), and 14/15 were seizure free. The difference in presence/absence of seizures between baseline and final follow-up was significant (p < 0.001). Responder rate was 100%. We observed five side-effects: four mild (reversible) and one severe. Logistic regression revealed that chemotherapy and radiotherapy did not affect the efficacy of LEV in seizure outcome (p = 0.999). The following statistically significant observations emerged by tests' evaluation: less worry about seizures, effects of antiepileptic, and ability to maintain social functions. Our data suggest that seizure occurrence can be an important warning sign that the clinician should heed throughout the duration of the illness. Patients with BTRE represent a unique patient population that presents difficulties regarding management of two very different pathologies: epilepsy on the one hand, and brain tumor on the other. Our data indicate that LEV, in patients with BTRE, is safe and efficacious, with positive impact on QoL. |
Mendeley readers
The data shown below were compiled from readership statistics for 81 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 1% |
| Netherlands | 1 | 1% |
| Unknown | 79 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 16 | 20% |
| Student > Ph. D. Student | 10 | 12% |
| Other | 8 | 10% |
| Student > Postgraduate | 8 | 10% |
| Student > Master | 7 | 9% |
| Other | 17 | 21% |
| Unknown | 15 | 19% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 36 | 44% |
| Neuroscience | 5 | 6% |
| Agricultural and Biological Sciences | 5 | 6% |
| Psychology | 4 | 5% |
| Nursing and Health Professions | 3 | 4% |
| Other | 8 | 10% |
| Unknown | 20 | 25% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 April 2011.
All research outputs
#15,233,109
of 22,649,029 outputs
Outputs from Journal of Neuro-Oncology
#1,936
of 2,954 outputs
Outputs of similar age
#140,171
of 179,822 outputs
Outputs of similar age from Journal of Neuro-Oncology
#9
of 11 outputs
Altmetric has tracked 22,649,029 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,954 research outputs from this source. They receive a mean Attention Score of 4.2. This one is in the 28th percentile – i.e., 28% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 179,822 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 12th percentile – i.e., 12% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 11 others from the same source and published within six weeks on either side of this one. This one is in the 9th percentile – i.e., 9% of its contemporaries scored the same or lower than it.